Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Home - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 712636 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
PDF Brochure
Send to Friend
Enquire before Buying
| More
Hard CopyAdd to Basket
EnterprisewideAdd to Basket



Thought Leader Insight & Analysis: Alzheimer's Disease
Medpredict, Jan 2008


  Description  
  Table of Contents  
  Products Mentioned  
    
    
   
 Enquire before Buying  
 Send to a Friend  

This report focuses on a variety of clinical approaches and diagnostics targeting either cognition or disease progression in Alzheimer’s disease. The report, #14 in the series, is based on seven interviews conducted with a cohort of national US peer-recognized AD experts. As 2008 begins the publisher’s Panelists were asked to review major developments this past year and to forecast the changes they expect to see in the Alzheimer’s competitive landscape in 2008. Each Panelist offers his perspective on those agents and mechanisms that have the strongest data supporting them, and comments on those where the excitement extends beyond the clinical evidence. These include acetylcholinesterase (butyrylcholinesterase) inhibitors, NMDA, M1, 5-HT, alpha-7 nicotinic acetylcholine agonists, active and passive immunotherapy, ?-secretase and ß-secretase inhibitors, insulin related mechanisms (IDE, RAGE), plasminogen activator inhibitor-1, anti-TNF, GSK3 and more. Given the size of the patient population and the lack of approved therapeutics that provide long-term disease control it is no surprise how many competitors are trying to commercialize drugs for this market. This in addition to the drugs highlighted as most interesting by the Panel the publisher offers in this report a program guide of new compounds, reflecting the many “shots on goal”. The publisher does this with the caveat that just because they name them doesn’t mean that they endorse them. The AD field is strewn with the bones of much hyped new chemical entities that did not stand up to closer scrutiny. But, they do provide a starting point for future Panel discussions.



Customers who bought this item also bought

Wyeth

Alzheimer Disease - New Drugs, Markets and Companies

Central Nervous System Alzheimer Disease

Alzheimer�s Disease - Drug Pipeline Analysis and Market Forecasts to 2015

Bapineuzumab Phase 2 Clinical Trial Results Call - Wyeth,Elan Corp. Plc, - Earnings Transcript

Bapineuzumab Phase 2 Clinical Trial Results Call - Wyeth,Elan Corp. Plc, - Earnings Transcript

Central Nervous System - Alzheimer Disease Drug Pipeline Report

Emerging Drug Targets in Alzheimer's Disease

Acquisition of Wyeth by Pfizer, Inc Call - - Earnings Transcript

Acquisition of Wyeth by Pfizer, Inc Call - - Earnings Transcript

Small Molecule Kinase Inhibitors - Global Strategic Business Report

CNS Drug Discoveries: Alzheimer's Disease Chapter



Top of page


   All rights reserved. � Copyright 2010 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster


Research and Markets RSS Feeds